View Older Stories View More Recent Stories

Feb 23, 2023 07:02AM Genprex (GNPX) Announces Data from Non-Human Primate Study Evaluating Novel Gene Therapy to Treat Type 1 Diabetes
Feb 23, 2023 07:00AM Genprex Announces Groundbreaking Data from Non-Human Primate Study Evaluating Novel Gene Therapy to Treat Type 1 Diabetes at 16th Annual International Conference on Advanced Technologies & Treatme
Jan 5, 2023 07:03AM Genprex (GNPX) Enters Exclusive License to Additional Diabetes Technology with the University of Pittsburgh
Jan 5, 2023 07:00AM Genprex Signs Exclusive License to Additional Diabetes Technology with the University of Pittsburgh
Jan 4, 2023 07:00AM Genprex Announces Selection of Preclinical Data for Oral Presentation at 16th International Conference on Advanced Technologies & Treatments for Diabetes
Dec 15, 2022 07:01AM Genprex (GNPX) Licenses Additional Technology from University of Pittsburgh
Dec 15, 2022 07:00AM Genprex Strengthens Diabetes Gene Therapy Program with License of Additional Technology from University of Pittsburgh
Dec 14, 2022 07:00AM Genprex Receives Safety Review Committee Approval to Proceed to Final Cohort in Acclaim-1 Phase 1 Dose Escalation Trial of REQORSA® in Combination with Tagrisso® in Advanced Non-Small Cell Lung Canc
Dec 2, 2022 08:15AM Genprex to Present at Upcoming December Investor Conference
Oct 7, 2022 07:45AM Genprex to Present at Upcoming October Investor and Industry Conferences
Sep 8, 2022 08:15AM Genprex to Present at Upcoming September Investor Conference
Aug 16, 2022 07:01AM Genprex (GNPX) Granted US Patent for REQORSA Immunogene Therapy
Aug 16, 2022 07:00AM Genprex Announces U.S. Patent for REQORSA™ Immunogene Therapy in Combination with Immune Checkpoint Inhibitors to Treat Cancers
Aug 15, 2022 07:00AM Genprex Announces Safety Review Committee Approves Dose Escalation in Acclaim-1 Phase 1/2 Trial of REQORSA™ in Combination with Tagrisso® in Non-Small Cell Lung Cancer
Jul 13, 2022 07:00AM Genprex to Participate in Next Generation Lipid-Based Nanoparticles Delivery Summit
Jun 2, 2022 07:00AM Genprex to Present at Upcoming June Investor Conferences
May 19, 2022 08:15AM Genprex to Present at Upcoming Investor Conference in May 2022
May 9, 2022 08:15AM Genprex's Chief Medical Officer to Be Featured as an Expert Panelist at the 33rd Annual Cancer Progress Conference
May 5, 2022 08:30AM Genprex Issues Shareholder Letter and Provides 2022 Corporate Update
Apr 18, 2022 08:15AM Genprex to Participate in Upcoming Investor and Industry Conferences in April 2022
Mar 31, 2022 07:05AM Genprex Announces the Opening for Enrollment of its Phase 1/2 Acclaim-2 Clinical Trial of REQORSA™ Immunogene Therapy in Combination With Keytruda® to Treat Non-Small Cell Lung Cancer
Mar 23, 2022 08:00AM Genprex to Participate in Upcoming Investor Conference in March
Mar 2, 2022 08:00AM Genprex Announces First Patient Dosed in Phase 1/2 Acclaim-1 Clinical Trial of REQORSA™ Immunogene Therapy in Combination with Tagrisso® to Treat Non-Small Cell Lung Cancer
Feb 9, 2022 08:15AM Genprex to Present at Upcoming Investor Conferences Highlighting its Gene Therapies for Cancer and Diabetes
Jan 27, 2022 11:24AM Genprex (GNPX) Announces Preclinical Data Show Potential for Use of ONCOPREX Nanoparticle Delivery System in Treating Colon Cancer
Jan 27, 2022 11:23AM Preclinical Data Show Potential for Use of Genprex’s ONCOPREX® Nanoparticle Delivery System in Treating Colon Cancer
Jan 10, 2022 09:17AM Genprex to Accelerate Opening of Acclaim-1 Clinical Trial Sites for REQORSA™ Systemic Gene Therapy in Non-Small Cell Lung Cancer
Jan 5, 2022 08:00AM Genprex to Participate in January Investor and Healthcare Conferences to Highlight Company’s Gene Therapies in Cancer and Diabetes
Jan 4, 2022 08:02AM Genprex (GNPX) Expands Gene Therapy Oncology Pipeline to Include Small Cell Lung Cancer
Jan 4, 2022 08:00AM Genprex Expands Gene Therapy Oncology Pipeline to Include Small Cell Lung Cancer
Jan 3, 2022 08:03AM Genprex (GNPX) Granted FDA Fast Track Designation for REQORSA in Combination With Keytruda
Jan 3, 2022 08:00AM Genprex Receives U.S. FDA Fast Track Designation for REQORSA™ Immunogene Therapy in Combination With Keytruda® for the Treatment of Non-Small Cell Lung Cancer
Nov 16, 2021 08:30AM Genprex to Present in November CEO Roadshow Webinar
Sep 28, 2021 06:51AM Genprex (GNPX) Announces Appointments of Mark S. Berger, M.D. as CMO and Hemant Kumar, Ph.D. as Chief Manufacturing and Technology Officer
Sep 28, 2021 06:50AM Genprex Strengthens Management Team with Appointments of Industry Leaders Mark S. Berger, M.D. as Chief Medical Officer and Hemant Kumar, Ph.D. as Chief Manufacturing and Technology Officer
Sep 20, 2021 07:00AM Genprex to Participate in September Investor Conferences
Jul 20, 2021 08:30AM Genprex to Participate in a Monthly CEO Roadshow Webinar Series
Jun 23, 2021 08:30AM Genprex Announces Initiation of its Phase 1/2 Acclaim-1 Clinical Trial for REQORSA™ Immunogene Therapy in Combination with Tagrisso® to Treat Non-Small Cell Lung Cancer Following FDA Review
May 19, 2021 08:30AM Genprex Announces Participation in Noble Capital Markets’ Virtual Roadshow Series
May 10, 2021 08:30AM Genprex to Participate in Upcoming May Investor Conferences
May 6, 2021 09:05AM Genprex In-Licenses Additional Gene Therapy Technologies for Treatment of Lung Cancer
May 5, 2021 08:55AM Genprex (GNPX) Announces Centralized Institutional Review Board Approval for Acclaim-1 Clinical Trial in Non-Small Cell Lung Cancer
May 5, 2021 08:55AM Genprex Announces Centralized Institutional Review Board Approval for Acclaim-1 Clinical Trial in Non-Small Cell Lung Cancer
May 4, 2021 09:32AM Genprex Initiates Site Recruitment for Acclaim-2 Clinical Trial for the Treatment of Non-Small Cell Lung Cancer
Apr 21, 2021 08:30AM Genprex to Participate in CEO Roadshow Webinar Series
Apr 20, 2021 08:30AM Genprex to Receive Inaugural “License of the Year” Award from University of Pittsburgh Innovation Institute in Recognition of Advances Made with Gene Therapy Program in Diabetes
Apr 12, 2021 08:37AM Genprex (GNPX) Collaborators Report Positive Preclinical Data for REQORSA Immunogene Therapy in Non-Small Cell Lung Cancer at AACR
Apr 12, 2021 08:30AM Genprex Collaborators Report Positive Preclinical Data for REQORSA™ Immunogene Therapy in Non-Small Cell Lung Cancer at the 2021 AACR Annual Meeting
Apr 5, 2021 08:30AM Genprex to Present at the 2021 Virtual Cell & Gene Meeting on the Mediterranean
Mar 30, 2021 08:32AM Genprex (GNPX) Announces Preclinical Data for TUSC2 Immunogene Therapy in Non-Small Cell Lung Cancer to Be Featured in Two Presentations at AACR
View More Recent Stories View Older Stories